Navigation Links
Curemark CM-AT Autism Treatment Granted FDA Fast Track Status

RYE, N.Y., Feb. 22 /PRNewswire/ -- Curemark LLC, (, a drug research and development company focused on the treatment of neurological diseases, announced that its CM-AT autism treatment, now in Phase III clinical trials, has been designated as a Fast Track drug by the U.S. Food and Drug Administration (FDA).  

Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious diseases and those that fill an unmet medical need, providing a therapy where none exists or are potentially superior to existing therapy, according to the FDA Web site.  Fast Track designation provides for early and frequent communication between the FDA and the drug company to resolve questions and issues quickly, obtaining an expedited review and faster access by patients.

"We are very excited about the FDA's Fast Track designation for CM-AT," said Dr. Joan Fallon, Curemark founder and CEO.  "We're making rapid progress with the CM-AT trials and being named as a Fast Track drug means that we potentially can get our autism treatment to market faster for the children and parents who will benefit from it."

CM-AT is based on Dr. Fallon's breakthrough research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function.  CM-AT will be one of the first therapies to address the underlying physiology of autism, rather than just treat its symptoms.

Curemark is conducting Phase III clinical trials for CM-AT at 12 sites across the country with a total 170 children.  Ten of the sites are now enrolling patients.

New data released in December by the U.S. Centers for Disease Control and Prevention (CDC) indicated that the number of children affected by autism is higher than originally thought.  According to the CDC, autism affects about 1 in 110 children.  


Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


Back to top
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. Curemark Closes Series A Financing
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Announces Senior Executive Promotions
5. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Study Finds Fever may Lead to Improved Behavior in Children with Autism Spectrum Disorders
9. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
10. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
11. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
Post Your Comments:
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ... NASDAQ: EPIX ) announced today that the first ... study of EPI-506 as a treatment for metastatic castration-resistant ... and Canada.  --> ... --> In the Phase 1/2 clinical trial, ESSA ...
(Date:11/24/2015)... --> --> According to ... Type (Bone Graft, Bine Graft Substitute, Platelet Rich Plasma, BMAC), ... Fusion), End User, and Geography - Global Forecast to 2020", ... Billion in 2014 and is expected to reach $2.4 Billion ... period of 2015 to 2020. Browse 55 market ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... Students and parents have something to be thankful for ... Real Impact awards. California Casualty is proud to support the contest designed ... and reckless driving, the number one killer of young drivers. , Almost 1,000 ...
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... ... now certified to offer their patients the many benefits of the revolutionary BIOLASE ... the sharp cutting and scraping tools traditionally used by a dentist in ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a wide ... Angela Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in Tucson, ... fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the patient ...
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... national leaders when it comes to several aspects of orthopedic care. They have ... replacements, orthopedic surgeries and general orthopedic care. , Becker's Hospital Review selected ...
Breaking Medicine News(10 mins):